摘要
目的探讨健择（GEM）联合卡铂（CBP）治疗卵巢癌的的疗效和毒副作用.方法 24例晚期卵巢癌患者给予GEM 1.2g/m^2,静脉滴入,30min,第1、8天;CBP400mg/m^2,静脉滴入,第1天.每3周为1个周期,2～3个周期后评价疗效和毒副反应.24例可评价疗效患者中,共计62个化疗周期.结果完全缓解（CR）3例,部分缓解（PR）8例,稳定（SD）9例,进展（PD）4例,总有效率（CR＋PR）45.8%（11/24）.10例初治患者有效率为60%（6/10）,14例复治患者有效率为35.7%（5/14）;化疗后白细胞减少发生率为100%,其中Ⅲ～Ⅳ度白细胞下降发生率为29.2%（7/24）.Ⅲ～Ⅳ度血小板下降20.8%（5/24）,Ⅲ～Ⅳ度血红蛋白下降16.7%（4/24）.非血液学毒性较轻.结论 GEM联合CBP是治疗卵巢癌疗效较好方案,主要毒性反应为血液学毒性.
Objective To investigate the efficacy and toxicity of combined therapy with gemcitabine （GEM） and carboplatin（CBP） in the treatment of ovarian cancer. Methods Twenty - four patients with ovarian cancer received combined chemotherapy of GEM and CBP, GEM 1.2 g/m^2 ,iv dl, d8; CBP400mg/m^2 iv dl, repeated every 21 days. Assessment was given after 2 or 3 cycles. Results The overall response rate was 45.8 % （ 11/24 ）, with the complete response （CR） 12.5 % （ 3 cases） and partial response 33.3 % （ 8 cases）. The response rate of the 14 relapsed patients was 35.7% （5/14） while those previously untreated patients was 60% （6/10）. The main toxicity was hematological toxicity, with 29.2% of patients affected at grade m or Ⅳ neutropenia. Conclusion GEM plus CBP is an active and well - tolerated regimen for patients with ovarian cancer. [ Key words] Ovarian carcinoma ; Gemcitabine ; Carboplatin ; Chemotherapy
出处
《中原医刊》
2006年第11期32-33,共2页
Central Plains Medical Journal
关键词
卵巢肿瘤
健择
卡铂
化疗
Ovarian carcinoma
Gemcitabine
Carboplatin
Chemotherapy
